Judith Strachan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Judith Strachan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Craig Mowat
University of Dundee School of Medicine
5 shared publications - Callum George Fraser
Population Health and Genomics , Ninewells Hospital and Medical School, University of Dundee , Dundee , UK
4 shared publications - Jayne Digby
School of Medicine University of Dundee Dundee UK
4 shared publications - Gavin R. C. Clark
Public Health Scotland Edinburgh UK
3 shared publications - Robert James Campbell Steele
Department of Surgery, Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, Scotland, UK
3 shared publications - Campbell MacLeod
Department of General Surgery, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN, UK
2 shared publications
Latest Publications
- Open Access
- 1 July 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (8) , 1544-1550
The impact of primary‐care led, faecal immunochemical test‐based, triage of new‐onset colorectal symptoms on time to diagnosis of colorectal cancer—An observational study
Aim: Since December 2015, a faecal immunochemical test (FIT) has been provided to primary care in NHS Tayside as an adjunct to clinical acumen in the assessment of new‐onset bowel symptoms. The aim of this work was to assess the impact of this approach on time to diagnosis of colorectal cancer (CRC).Method: NHS Tayside Cancer audit data from January 2013 to December 2019 were reviewed to identify all CRC patients diagnosed via the primary‐care referral pathway for a period before and after the introduction of FIT. Their electronic patient records were accessed and date of referral and any contemporaneous FIT and full blood count (FBC) result were recorded. Time from referral to diagnosis of CRC was calculated for each patient and compared between subgroups.Results: The study cohort consisted of 959 patients: 378 and 581 from the time periods before and after the introduction of FIT, respectively. The median time to diagnosis before FIT was 30 days [interquartile range (IQR) 16–57 days] versus 25 days (IQR 14–47 days) following the introduction of FIT (p = 0.006). Following the introduction of FIT, patients who completed a FIT had a median of time to diagnosis of 23 days (IQR 14–43 days) compared with 30 days (IQR 16–62 days) for patients not completing a FIT (p = 0.019). FBC results were available for 97.5% of FIT patients to aid safety‐netting of patients with a low or undetectable faecal haemoglobin concentration.Conclusion: The introduction of FIT‐based triage of new bowel symptoms in primary care as an adjunct to clinical acumen is associated with a reduced time to CRC diagnosis.
- 1 July 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (8) , 1544-1550
Open AccessThe impact of primary‐care led, faecal immunochemical test‐based, triage of new‐onset colorectal symptoms on time to diagnosis of colorectal cancer—An observational study
Aim: Since December 2015, a faecal immunochemical test (FIT) has been provided to primary care in NHS Tayside as an adjunct to clinical acumen in the assessment of new‐onset bowel symptoms. The aim of this work was to assess the impact of this approach on time to diagnosis of colorectal cancer (CRC).Method: NHS Tayside Cancer audit data from January 2013 to December 2019 were reviewed to identify all CRC patients diagnosed via the primary‐care referral pathway for a period before and after the introduction of FIT. Their electronic patient records were accessed and date of referral and any contemporaneous FIT and full blood count (FBC) result were recorded. Time from referral to diagnosis of CRC was calculated for each patient and compared between subgroups.Results: The study cohort consisted of 959 patients: 378 and 581 from the time periods before and after the introduction of FIT, respectively. The median time to diagnosis before FIT was 30 days [interquartile range (IQR) 16–57 days] versus 25 days (IQR 14–47 days) following the introduction of FIT (p = 0.006). Following the introduction of FIT, patients who completed a FIT had a median of time to diagnosis of 23 days (IQR 14–43 days) compared with 30 days (IQR 16–62 days) for patients not completing a FIT (p = 0.019). FBC results were available for 97.5% of FIT patients to aid safety‐netting of patients with a low or undetectable faecal haemoglobin concentration.Conclusion: The introduction of FIT‐based triage of new bowel symptoms in primary care as an adjunct to clinical acumen is associated with a reduced time to CRC diagnosis.
- 29 February 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (4) , 675-683
Do risk scores improve use of faecal immunochemical testing for haemoglobin in symptomatic patients in primary care?
Aim: Faecal immunochemical testing (FIT) is used in the detection of colorectal cancer (CRC). FIT is invariably used at a single faecal haemoglobin (f‐Hb) concentration threshold. The aim of this observational study was to explore risk scoring models (RSMs) with f‐Hb and other risk factors for CRC in symptomatic patients attending primary care, potentially speeding diagnosis and saving endoscopy resources.Method: Records of patients completing FIT were linked with The Scottish Cancer Registry and with other databases with symptoms, full blood count and demographic variables, and randomized into derivation and validation cohorts. Stepwise multivariable logistic regression created RSMs assessed in the validation cohort.Results: Of 18 805 unique patients, 9374 and 9431 were in the derivation and validation cohorts, respectively: f‐Hb, male sex, increasing age, iron deficiency anaemia and raised systemic immune inflammation index created the final RSM. A risk score threshold of ≥2.363, generating the same number of colonoscopies as a f‐Hb threshold of ≥10 μg Hb/g gave improved sensitivity for CRC in both cohorts. A RSM which excluded f‐Hb was used to investigate the effect of raising the f‐Hb threshold from ≥10 to ≥20 μg Hb/g in those with a low risk score. This approach would have generated 234 fewer colonoscopies but missed four CRCs.Conclusion: The RSM conferred no significant benefit to patients with very low f‐Hb and CRC. Alternative strategies combining FIT with other variables may be more appropriate for safety‐netting of symptomatic patients. Further work to develop and investigate the value of RSM for significant bowel disease other than CRC may also be beneficial.
- 29 February 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (4) , 675-683
Do risk scores improve use of faecal immunochemical testing for haemoglobin in symptomatic patients in primary care?
Aim: Faecal immunochemical testing (FIT) is used in the detection of colorectal cancer (CRC). FIT is invariably used at a single faecal haemoglobin (f‐Hb) concentration threshold. The aim of this observational study was to explore risk scoring models (RSMs) with f‐Hb and other risk factors for CRC in symptomatic patients attending primary care, potentially speeding diagnosis and saving endoscopy resources.Method: Records of patients completing FIT were linked with The Scottish Cancer Registry and with other databases with symptoms, full blood count and demographic variables, and randomized into derivation and validation cohorts. Stepwise multivariable logistic regression created RSMs assessed in the validation cohort.Results: Of 18 805 unique patients, 9374 and 9431 were in the derivation and validation cohorts, respectively: f‐Hb, male sex, increasing age, iron deficiency anaemia and raised systemic immune inflammation index created the final RSM. A risk score threshold of ≥2.363, generating the same number of colonoscopies as a f‐Hb threshold of ≥10 μg Hb/g gave improved sensitivity for CRC in both cohorts. A RSM which excluded f‐Hb was used to investigate the effect of raising the f‐Hb threshold from ≥10 to ≥20 μg Hb/g in those with a low risk score. This approach would have generated 234 fewer colonoscopies but missed four CRCs.Conclusion: The RSM conferred no significant benefit to patients with very low f‐Hb and CRC. Alternative strategies combining FIT with other variables may be more appropriate for safety‐netting of symptomatic patients. Further work to develop and investigate the value of RSM for significant bowel disease other than CRC may also be beneficial.
- Open Access
- 3 January 2024
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 8 (1)
Colon capsule endoscopy investigation based on faecal haemoglobin concentration in symptomatic patients to detect bowel disease
The faecal immunochemical test (FIT), which measures the concentration of faecal haemoglobin (f-Hb), is now advocated by the Association of Coloproctology of Great Britain and Ireland and the British Society of Gastroenterology for use in primary care as an adjunct to clinical acumen in the assessment of new bowel symptoms1. FIT is superior to symptoms at predicting the presence of significant bowel disease (SBD)2–4. Higher f-Hb concentrations correspond with an increased risk of harbouring colorectal pathology and as such can be used to prioritize patients for investigation.
- 3 January 2024
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 8 (1)
Open AccessColon capsule endoscopy investigation based on faecal haemoglobin concentration in symptomatic patients to detect bowel disease
The faecal immunochemical test (FIT), which measures the concentration of faecal haemoglobin (f-Hb), is now advocated by the Association of Coloproctology of Great Britain and Ireland and the British Society of Gastroenterology for use in primary care as an adjunct to clinical acumen in the assessment of new bowel symptoms1. FIT is superior to symptoms at predicting the presence of significant bowel disease (SBD)2–4. Higher f-Hb concentrations correspond with an increased risk of harbouring colorectal pathology and as such can be used to prioritize patients for investigation.
- Open Access
- 19 July 2023
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 31 (1) , 21-27
Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality
Objective: To compare interval cancer proportions (ICP) in the faecal immunochemical test (FIT)-based Scottish Bowel Screening Programme (SBoSP) with the former guaiac faecal occult blood test (gFOBT)-based SBoSP and investigate associations between interval cancer (IC) and faecal haemoglobin concentration (f-Hb) threshold, sex, age, deprivation, site, and stage. Methods: The ICP data from first year of the FIT-based SBoSP and the penultimate year of the gFOBT-based SBoSP were compared in a prospective cohort design. Results: With FIT, 801 colorectal cancers (CRCs) were screen detected (SDC), 802 were in non-participants, 548 were ICs, 39 were colonoscopy missed and 72 were diagnosed after incomplete screening; with gFOBT: 540, 904, 556, 45, and 13, respectively. FIT had a significantly higher proportion of SDC compared to IC than gFOBT. For FIT and gFOBT, ICP was significantly higher in women than men. As f-Hb threshold increased, ICP increased and, for any f-Hb threshold for men, a lower threshold was required for comparable ICP in women. In Scotland, the current threshold of ≥80 µg Hb/g faeces would have to be lowered to ≥40 µg Hb/g faeces for women to achieve sex equality for ICP. In the FIT-based SBoSP, there were four times as many stage I SDC than IC. This was reversed in advanced stages, with twice as many stage IV CRC diagnosed as IC versus SDC. Conclusions: Reducing the numbers of IC requires lowering the f-Hb threshold. Using different f-Hb thresholds for women and men could eliminate the sex disparity, but with additional colonoscopy.
- 19 July 2023
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 31 (1) , 21-27
Open AccessInterval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality
Objective: To compare interval cancer proportions (ICP) in the faecal immunochemical test (FIT)-based Scottish Bowel Screening Programme (SBoSP) with the former guaiac faecal occult blood test (gFOBT)-based SBoSP and investigate associations between interval cancer (IC) and faecal haemoglobin concentration (f-Hb) threshold, sex, age, deprivation, site, and stage. Methods: The ICP data from first year of the FIT-based SBoSP and the penultimate year of the gFOBT-based SBoSP were compared in a prospective cohort design. Results: With FIT, 801 colorectal cancers (CRCs) were screen detected (SDC), 802 were in non-participants, 548 were ICs, 39 were colonoscopy missed and 72 were diagnosed after incomplete screening; with gFOBT: 540, 904, 556, 45, and 13, respectively. FIT had a significantly higher proportion of SDC compared to IC than gFOBT. For FIT and gFOBT, ICP was significantly higher in women than men. As f-Hb threshold increased, ICP increased and, for any f-Hb threshold for men, a lower threshold was required for comparable ICP in women. In Scotland, the current threshold of ≥80 µg Hb/g faeces would have to be lowered to ≥40 µg Hb/g faeces for women to achieve sex equality for ICP. In the FIT-based SBoSP, there were four times as many stage I SDC than IC. This was reversed in advanced stages, with twice as many stage IV CRC diagnosed as IC versus SDC. Conclusions: Reducing the numbers of IC requires lowering the f-Hb threshold. Using different f-Hb thresholds for women and men could eliminate the sex disparity, but with additional colonoscopy.
- Open Access
- 27 February 2023
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 33 (2) , 331-335
Sex variation in colorectal cancer mortality: trends and implications for screening
Background: Colorectal cancer (CRC) screening using faecal tests reduces disease-specific mortality. To investigate mortality and its association with sex, rates in women and men, and in different age ranges, were examined, before and after screening began in Scotland. Methods: From 1990–99, no structured screening existed. Three pilots ran from 2000 to 2007 and subsequent full roll-out completed in 2009. Crude mortality rates for 1990–2020 were calculated relative to Scottish population estimates, and age–sex standardized rates calculated for all, pre-screening (74 years) age ranges. Results: CRC mortality declined from 1990 to 2020, but not linearly, and differed between sexes. In women, 1990–99 showed a steady decline [average annual percentage change (AAPC): −2.1%, 95% confidence interval (CI): −2.8% to −1.4%], but a less marked decline after 2000 (AAPC: −0.7%, 95% CI: −0.9% to −0.4%). In men, no clear decline was seen from 1990 to 1999 (AAPC: −0.4%, 95% CI: −1.1% to 0.4%), but mortality declined from 2000 to 2020 (AAPC: −1.7%, 95% CI: −1.9% to −1.5%). This pattern was exaggerated in the screening age ranges. For 2000–20, the overall reduction in mortality was less in women and in the screening age range. In the post-screening age range, reductions were smaller, but an increase was seen in the pre-screening age range, greater in women. Conclusions: CRC mortality fell during 1990–2020, but the decline differed markedly between sexes, indicating a larger beneficial effect of screening on CRC mortality in men compared to women: use of different thresholds for the sexes might lead to equality.
- 27 February 2023
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 33 (2) , 331-335
Open AccessSex variation in colorectal cancer mortality: trends and implications for screening
Background: Colorectal cancer (CRC) screening using faecal tests reduces disease-specific mortality. To investigate mortality and its association with sex, rates in women and men, and in different age ranges, were examined, before and after screening began in Scotland. Methods: From 1990–99, no structured screening existed. Three pilots ran from 2000 to 2007 and subsequent full roll-out completed in 2009. Crude mortality rates for 1990–2020 were calculated relative to Scottish population estimates, and age–sex standardized rates calculated for all, pre-screening (74 years) age ranges. Results: CRC mortality declined from 1990 to 2020, but not linearly, and differed between sexes. In women, 1990–99 showed a steady decline [average annual percentage change (AAPC): −2.1%, 95% confidence interval (CI): −2.8% to −1.4%], but a less marked decline after 2000 (AAPC: −0.7%, 95% CI: −0.9% to −0.4%). In men, no clear decline was seen from 1990 to 1999 (AAPC: −0.4%, 95% CI: −1.1% to 0.4%), but mortality declined from 2000 to 2020 (AAPC: −1.7%, 95% CI: −1.9% to −1.5%). This pattern was exaggerated in the screening age ranges. For 2000–20, the overall reduction in mortality was less in women and in the screening age range. In the post-screening age range, reductions were smaller, but an increase was seen in the pre-screening age range, greater in women. Conclusions: CRC mortality fell during 1990–2020, but the decline differed markedly between sexes, indicating a larger beneficial effect of screening on CRC mortality in men compared to women: use of different thresholds for the sexes might lead to equality.
- Open Access
- 18 July 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1498-1504
Prevalence of repeat faecal immunochemical testing in symptomatic patients attending primary care
Aim: The faecal immunochemical test (FIT) for faecal haemoglobin (f‐Hb) helps determine the risk of colorectal cancer (CRC) and has been integrated into symptomatic referral pathways. ‘Safety netting’ advice includes considering referral for persistent symptoms, but no published data exists on repeated FITs. We aimed to examine the prevalence of serial FITs in primary care and CRC risk in these patients.Method: A multicentre, retrospective, observational study was conducted of patients with two or more consecutive f‐Hb results within a year from three Scottish Health Boards which utilize FIT in primary care. Cancer registry data ensured identification of CRC cases.Results: Overall, 135 396 FIT results were reviewed, of which 12 359 were serial results reported within 12 months (9.1%), derived from 5761 patients. Of these, 42 (0.7%) were diagnosed with CRC. A total of 3487 (60.5%) patients had two f‐Hb < 10 μg/g, 944 (16.4%) had f‐Hb ≥ 10 μg/g followed by <10 μg/g, 704 (12.2%) f‐Hb < 10 μg/g followed by ≥10 μg/g and 626 (10.9%) had two f‐Hb ≥ 10 μg/g. The CRC rate in each group was 0.1%, 0.4%, 1.4% and 4.0%, respectively. Seven hundred and thirty four patients submitted more than two FITs within a year. The likelihood of one or more f‐Hb ≥ 10 μg/g rose from 40.4% with two samples to 100% with six, while the CRC rate fell from 0.8% to 0%.Conclusion: Serial FITs within a year account for 9.1% of all results in our Boards. CRC prevalence amongst symptomatic patients with serial FIT is lower than in single‐FIT cohorts. Performing two FITs within a year for patients with persistent symptoms effectively acts as a safety net, while performing more than two within this timeframe is unlikely to be beneficial.
- 18 July 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1498-1504
Open AccessPrevalence of repeat faecal immunochemical testing in symptomatic patients attending primary care
Aim: The faecal immunochemical test (FIT) for faecal haemoglobin (f‐Hb) helps determine the risk of colorectal cancer (CRC) and has been integrated into symptomatic referral pathways. ‘Safety netting’ advice includes considering referral for persistent symptoms, but no published data exists on repeated FITs. We aimed to examine the prevalence of serial FITs in primary care and CRC risk in these patients.Method: A multicentre, retrospective, observational study was conducted of patients with two or more consecutive f‐Hb results within a year from three Scottish Health Boards which utilize FIT in primary care. Cancer registry data ensured identification of CRC cases.Results: Overall, 135 396 FIT results were reviewed, of which 12 359 were serial results reported within 12 months (9.1%), derived from 5761 patients. Of these, 42 (0.7%) were diagnosed with CRC. A total of 3487 (60.5%) patients had two f‐Hb < 10 μg/g, 944 (16.4%) had f‐Hb ≥ 10 μg/g followed by <10 μg/g, 704 (12.2%) f‐Hb < 10 μg/g followed by ≥10 μg/g and 626 (10.9%) had two f‐Hb ≥ 10 μg/g. The CRC rate in each group was 0.1%, 0.4%, 1.4% and 4.0%, respectively. Seven hundred and thirty four patients submitted more than two FITs within a year. The likelihood of one or more f‐Hb ≥ 10 μg/g rose from 40.4% with two samples to 100% with six, while the CRC rate fell from 0.8% to 0%.Conclusion: Serial FITs within a year account for 9.1% of all results in our Boards. CRC prevalence amongst symptomatic patients with serial FIT is lower than in single‐FIT cohorts. Performing two FITs within a year for patients with persistent symptoms effectively acts as a safety net, while performing more than two within this timeframe is unlikely to be beneficial.
- Open Access
- 2 March 2022
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 59 (4) , 272-276
Faecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker
Background: Polypectomy may be performed at colonoscopy and then subsequent surveillance undertaken. It is thought that faecal haemoglobin concentration (f-Hb), estimated by quantitative faecal immunochemical tests (FIT), might be a useful tumour marker. Methods: Consecutive patients enrolled in colonoscopy surveillance were approached at two hospitals. A specimen for FIT was provided before colonoscopy and, ideally after 3 weeks, a second FIT sample from those who had polypectomy. A single FIT system (OC-Sensor io, Eiken Chemical Co., Ltd) was used to generate f-Hb. Results: 1103 Patients were invited; 643 returned a FIT device (uptake: 58.3%). Four patients had known inflammatory bowel disease (IBD) and were excluded, leaving 639 (57.9%) with an age range of 25–90 years (median 64 years), 54.6% male. Of 593 patients who had a f-Hb result and completed colonoscopy, advanced neoplasia was found in 41 (6.9%); four colorectal cancer (CRC): 0.7% and 37 advanced adenoma (AA): 6.3%, and a further 127 (21.4%) had non-advanced adenoma (NAA). The median f-Hb was significantly greater in AA as compared to NAA; 6.0 versus 1.0 μg Hb/g faeces, p < 0.0001.134/164 (81.7%) of invited patients returned a second FIT device: 28 were patients with AA in whom median pre-polypectomy f-Hb was 19.2, falling to 3.5 μg Hb/g faeces post-polypectomy, p = 0.01, and 106 with NAA had median pre-polypectomy f-Hb 0.8 compared to 1.0 μg Hb/g faeces post-polypectomy, p = 0.96. Conclusions: Quantitative FIT could provide a good tumour marker in post-polypectomy surveillance, reduce colonoscopy requirements and minimise potential risk to patients.
- 2 March 2022
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 59 (4) , 272-276
Open AccessFaecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker
Background: Polypectomy may be performed at colonoscopy and then subsequent surveillance undertaken. It is thought that faecal haemoglobin concentration (f-Hb), estimated by quantitative faecal immunochemical tests (FIT), might be a useful tumour marker. Methods: Consecutive patients enrolled in colonoscopy surveillance were approached at two hospitals. A specimen for FIT was provided before colonoscopy and, ideally after 3 weeks, a second FIT sample from those who had polypectomy. A single FIT system (OC-Sensor io, Eiken Chemical Co., Ltd) was used to generate f-Hb. Results: 1103 Patients were invited; 643 returned a FIT device (uptake: 58.3%). Four patients had known inflammatory bowel disease (IBD) and were excluded, leaving 639 (57.9%) with an age range of 25–90 years (median 64 years), 54.6% male. Of 593 patients who had a f-Hb result and completed colonoscopy, advanced neoplasia was found in 41 (6.9%); four colorectal cancer (CRC): 0.7% and 37 advanced adenoma (AA): 6.3%, and a further 127 (21.4%) had non-advanced adenoma (NAA). The median f-Hb was significantly greater in AA as compared to NAA; 6.0 versus 1.0 μg Hb/g faeces, p < 0.0001.134/164 (81.7%) of invited patients returned a second FIT device: 28 were patients with AA in whom median pre-polypectomy f-Hb was 19.2, falling to 3.5 μg Hb/g faeces post-polypectomy, p = 0.01, and 106 with NAA had median pre-polypectomy f-Hb 0.8 compared to 1.0 μg Hb/g faeces post-polypectomy, p = 0.96. Conclusions: Quantitative FIT could provide a good tumour marker in post-polypectomy surveillance, reduce colonoscopy requirements and minimise potential risk to patients.